Abstract
The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
Current Drug Targets
Title: New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets
Volume: 9 Issue: 5
Author(s): Tommaso Stefanelli, Alberto Malesci, Alessandro Repici, Stefania Vetrano and Silvio Danese
Affiliation:
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
Abstract: The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Export Options
About this article
Cite this article as:
Stefanelli Tommaso, Malesci Alberto, Repici Alessandro, Vetrano Stefania and Danese Silvio, New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets, Current Drug Targets 2008; 9 (5) . https://dx.doi.org/10.2174/138945008784221170
DOI https://dx.doi.org/10.2174/138945008784221170 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry PPARγ and Early Human Placental Development
Current Medicinal Chemistry Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment Targets
Current Pharmaceutical Design Treatment of Graves Hyperthyroidism with Thionamides-Derived Drugs: Review
Medicinal Chemistry